These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114 [TBL] [Abstract][Full Text] [Related]
3. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Leneva IA; Roberts N; Govorkova EA; Goloubeva OG; Webster RG Antiviral Res; 2000 Nov; 48(2):101-15. PubMed ID: 11114412 [TBL] [Abstract][Full Text] [Related]
5. Oseltamivir: a review of its use in influenza. McClellan K; Perry CM Drugs; 2001; 61(2):263-83. PubMed ID: 11270942 [TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. He G; Massarella J; Ward P Clin Pharmacokinet; 1999 Dec; 37(6):471-84. PubMed ID: 10628898 [TBL] [Abstract][Full Text] [Related]
7. Neuraminidase inhibitors for preventing and treating influenza in children. Matheson NJ; Symmonds-Abrahams M; Sheikh A; Shepperd S; Harnden A Cochrane Database Syst Rev; 2003; (3):CD002744. PubMed ID: 12917931 [TBL] [Abstract][Full Text] [Related]
8. [Epidemiology, clinical picture, prevention and treatment of Avian influenza]. Angelava NA; Angelava AV Georgian Med News; 2006 Feb; (131):69-76. PubMed ID: 16575138 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719 [TBL] [Abstract][Full Text] [Related]
10. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248 [TBL] [Abstract][Full Text] [Related]
11. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Hill G; Cihlar T; Oo C; Ho ES; Prior K; Wiltshire H; Barrett J; Liu B; Ward P Drug Metab Dispos; 2002 Jan; 30(1):13-9. PubMed ID: 11744606 [TBL] [Abstract][Full Text] [Related]
12. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Recomm Rep; 1999 Dec; 48(RR-14):1-9. PubMed ID: 10632443 [TBL] [Abstract][Full Text] [Related]
17. Antivirals for influenza in healthy adults: systematic review. Jefferson T; Demicheli V; Rivetti D; Jones M; Di Pietrantonj C; Rivetti A Lancet; 2006 Jan; 367(9507):303-13. PubMed ID: 16443037 [TBL] [Abstract][Full Text] [Related]
18. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516 [TBL] [Abstract][Full Text] [Related]